<DOC>
	<DOC>NCT00203151</DOC>
	<brief_summary>It is thought that Edratide may be able to reduce the symptoms of SLE.</brief_summary>
	<brief_title>A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>1. Willing and able to give written informed consent 2. Between the ages of 18 and 65 years (inclusive) 3. Fulfilled at least 4 ACR classification criteria 4. SLE patients with moderate, active disease 5. Subjects on stable dose of SLE medications for at least 4 weeks before randomization. 6. Women of childbearing potential must practice a medically acceptable method of contraception.. 7. Must understand the requirements of the study and agree to comply with the study protocol. 1. Any condition which the investigator feels may interfere with participation in the study. 2. Subjects having a history of chronic infection 3. Subjects with a history of immunodeficiency syndrome or malignancy, 4. Subjects who received any investigational medication (including DHEA) within 3 months prior to randomization, 5. Subjects treated with any cytotoxic agents in the 3 months prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>